All Press Releases for November 01, 2021

A New Cardiovascular Medical Device is Being Developed at Ensil Inc. which will Diagnose Diseases, Injuries, and Congenital Problems Affecting the Heart

The new device replaces older technologies traditionally used for Electrocardiograms (ECG), Stress Tests, Holter Monitors, Event Recorders, Tilt Table Tests, and the Electrophysiology Study.

Ensil has achieved successful test results for "Estcorsalutem", a medical device which can replace several medical technologies that are traditionally used in the field of cardiology.

    MARKHAM, ON, November 01, 2021 /24-7PressRelease/ -- This morning, Ensil Inc. announced the exciting news that its team of researchers and engineers have made a major breakthrough in the development of a revolutionary medical device that will help patients who suffer from cardiovascular problems and heart disease more broadly.

Farsad Kiani, President and CEO of Ensil Inc. stated: "Ensil Inc. has achieved successful test results for its first model of "Estcorsalutem", which can replace several medical devices currently in use for the test and diagnosis of problems such as disease, injury, and congenital problems related to cardiovascular health."

Now that Ensil has manufactured a series of successful prototypes for its first model of "Estcorsalutem", it is ready to partner with a number of working cardiologists to undergo further testing and validation. This partnering and relationship-building will be overseen by a best-in-class MD Cardiologist through an MOU (Memorandum of Understanding). The team will also complete the registration of "Estcorsalutem" as a class two medical device with an application submission of 510(k) covering regulation number 870.1120. With these processes complete, Ensil hopes to ultimately offer this device to cardiologists and medical facilities worldwide.

"We are very confident and proud that we have developed a product at our Markham, Ontario, Canada facilities that will help tens of thousands of people who suffer from cardiovascular issues," said Farsad Kiani, CEO of Ensil Inc. "This is a phenomenal first step. It is our hope that we can bring this product to market, so that people can continue enjoying their regular day-to-day activities without the added hindrances cardiovascular disease burdens them with."

Today's announcement comes from one of the many areas of research Ensil Inc. works in––with the goal of improving people's lives around the world. Over the past three decades, Ensil Inc. has made many positive breakthroughs and has worked in and with communities to improve people's health and well-being. Recent work has included major advancements in devices that aid the quality of the life of those who have been affected by strokes, Multiple Sclerosis, spinal cord injuries, and paralysis.

Ensil Inc., a member of Ensil group of companies (, focuses on enhancing mission critical technologies in the areas of Aerospace, Defence and Medical Diagnostic Equipment. Ensil's Research and Development divisions' mission is to develop new technologies and improve existing technologies through its own in-house research activities and resources.

While our reputation is backed by our history of excellence, our true strength comes from our incredible employees and their tireless drive for success. Their technological innovations and breakthroughs have become our legacy.

For further information please contact us at: [email protected] or visit us at WWW.ENSIL.COM

# # #

Contact Information

Farsad Kiani
Ensil Inc.
Markham, Ontario
Voice: 416-301-1180
E-Mail: Email Us Here
Website: Visit Our Website
Follow Us: